|
| Status |
Public on Jul 28, 2010 |
| Title |
14C: Letrozole, 2.5mg/day,oral, 90 days; responder |
| Sample type |
RNA |
| |
|
| Source name |
14C
|
| Organism |
Homo sapiens |
| Characteristics |
subject: 14
gender: female
tissue: breast tumor
agent: Letrozol
dose: 2.5mg/day
administration: oral
time: 90 days
|
| Treatment protocol |
breast biopsies were taken from subjects after 90 days Letrozol, 2.5 mg
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Biopsies were snap-frozen after collection and stored in liquid nitrogen. Frozen sections were taken prior to RNA extraction to confirm the presence of cancerous tissue within the specimens. Only samples in which the malignant component comprised at least 20% of the section area were used in further analyses. Immediately before RNA extraction the biopsies were pulverised using U2 micro-dismembranator U (Braun Biotech). Total RNA was extracted from the resultant frozen tissue powder using TRI-reagent (Sigma) according to the manufacturer's recommendations. Extracted RNA was additionally purified on RNeasy mini columns (Qiagen). RNA quantity and quality was verified on Bioanalyser 2100 (Agilent).
|
| Label |
biotin
|
| Label protocol |
Approximately 500 ng of total RNA was processed to produce biotinylated cRNA targets using protocol described in Biotechniques. 2003 Mar;34(3):546-50, 552-4, 556
|
| |
|
| Hybridization protocol |
standard Affymetrix procedures except for use of a custom 24-channel fluidics machine
|
| Scan protocol |
standard Affymetrix procedures
|
| Description |
breast tumor biopsy
|
| Data processing |
MAS5
|
| |
|
| Submission date |
Feb 03, 2010 |
| Last update date |
Oct 13, 2010 |
| Contact name |
John R Walker |
| E-mail(s) |
[email protected]
|
| Phone |
858-812-1636
|
| Organization name |
Genomics Institute of the Novartis Research Foundation
|
| Lab |
Genetics Core
|
| Street address |
10675 John Jay Hopkins
|
| City |
San Diego |
| State/province |
CA |
| ZIP/Postal code |
92121 |
| Country |
USA |
| |
|
| Platform ID |
GPL96 |
| Series (1) |
| GSE20181 |
Letrozole (Femara) early and late responses to treatment |
|
